STAT3 and prostate carcinoma: Of note, IL-6 mediates STAT3 activation and shows unique functions in androgen-dependent prostate cancer progression to the neuroendocrine differentiation stage that is clinically called neuroendocrine prostate cancer [42, 43], so far, there are no effective therapeutic strategies.